Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SynAct Pharma AB ( (SE:SYNACT) ) has shared an announcement.
SynAct Pharma AB is inviting investors, analysts, and media to its Capital Markets Day on June 4, 2025, in Stockholm. The event will provide updates on the company’s Phase 2b ADVANCE study for rheumatoid arthritis and plans to expand the use of resomelagon into other indications, highlighting SynAct’s strategic efforts to enhance its market positioning in the biotechnology sector.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company is actively involved in developing treatments for inflammatory and autoimmune diseases, with a particular emphasis on rheumatoid arthritis.
Average Trading Volume: 205,175
Current Market Cap: SEK756.7M
For an in-depth examination of SYNACT stock, go to TipRanks’ Stock Analysis page.